BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38246400)

  • 1. The impact of fibroid treatments on quality of life and mental health: a systematic review.
    Neumann B; Singh B; Brennan J; Blanck J; Segars JH
    Fertil Steril; 2024 Mar; 121(3):400-425. PubMed ID: 38246400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of the psychosocial impact of fibroids before and after treatment.
    Go VAA; Thomas MC; Singh B; Prenatt S; Sims H; Blanck JF; Segars JH
    Am J Obstet Gynecol; 2020 Nov; 223(5):674-708.e8. PubMed ID: 32474012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
    Murji A; Whitaker L; Chow TL; Sobel ML
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The management of uterine fibroids in women with otherwise unexplained infertility.
    Carranza-Mamane B; Havelock J; Hemmings R; ;
    J Obstet Gynaecol Can; 2015 Mar; 37(3):277-285. PubMed ID: 26001875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life with relugolix combination therapy for uterine fibroids: LIBERTY randomized trials.
    Stewart EA; Lukes AS; Venturella R; Li Y; Hunsche E; Wagman RB; Al-Hendy A
    Am J Obstet Gynecol; 2023 Mar; 228(3):320.e1-320.e11. PubMed ID: 36370871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The management of uterine leiomyomas.
    Vilos GA; Allaire C; Laberge PY; Leyland N;
    J Obstet Gynaecol Can; 2015 Feb; 37(2):157-178. PubMed ID: 25767949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibroid interventions: reducing symptoms today and tomorrow: extending generalizability by using a comprehensive cohort design with a randomized controlled trial.
    AbdElmagied AM; Vaughan LE; Weaver AL; Laughlin-Tommaso SK; Hesley GK; Woodrum DA; Jacoby VL; Kohi MP; Price TM; Nieves A; Miller MJ; Borah BJ; Gorny KR; Leppert PC; Lemens MA; Stewart EA
    Am J Obstet Gynecol; 2016 Sep; 215(3):338.e1-338.e18. PubMed ID: 27073063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term health-related quality of life and symptom severity following hysterectomy, myomectomy, or uterine artery embolization for the treatment of symptomatic uterine fibroids.
    Anchan RM; Spies JB; Zhang S; Wojdyla D; Bortoletto P; Terry K; Disler E; Milne A; Gargiulo A; Petrozza J; Brook O; Srouji S; Morton CC; Greenberg J; Wegienka G; Stewart EA; Nicholson WK; Thomas L; Venable S; Laughlin-Tommaso S; Diamond MP; Maxwell GL; Marsh EE; Myers ER; Vines AI; Wise LA; Wallace K; Jacoby VL
    Am J Obstet Gynecol; 2023 Sep; 229(3):275.e1-275.e17. PubMed ID: 37244458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Systematic Review of Minimally Invasive Approaches to Uterine Fibroid Treatment for Improving Quality of Life and Fibroid-Associated Symptoms.
    Morris JM; Liang A; Fleckenstein K; Singh B; Segars J
    Reprod Sci; 2023 May; 30(5):1495-1505. PubMed ID: 36401073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing research in symptomatic uterine fibroids with development of a computable phenotype for use with electronic health records.
    Hoffman SR; Vines AI; Halladay JR; Pfaff E; Schiff L; Westreich D; Sundaresan A; Johnson LS; Nicholson WK
    Am J Obstet Gynecol; 2018 Jun; 218(6):610.e1-610.e7. PubMed ID: 29432754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Comparing Options for Management: PAtient-centered REsults for Uterine Fibroids (COMPARE-UF) registry: rationale and design.
    Stewart EA; Lytle BL; Thomas L; Wegienka GR; Jacoby V; Diamond MP; Nicholson WK; Anchan RM; Venable S; Wallace K; Marsh EE; Maxwell GL; Borah BJ; Catherino WH; Myers ER
    Am J Obstet Gynecol; 2018 Jul; 219(1):95.e1-95.e10. PubMed ID: 29750955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Add-back therapy with GnRH analogues for uterine fibroids.
    Moroni RM; Martins WP; Ferriani RA; Vieira CS; Nastri CO; Candido Dos Reis FJ; Brito LG
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010854. PubMed ID: 25793972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative medical therapy before surgery for uterine fibroids.
    Lethaby A; Puscasiu L; Vollenhoven B
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD000547. PubMed ID: 29139105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of diagnosis and treatment of uterine fibroids on quality of life and labor productivity: The Japanese online survey for uterine fibroids and quality of life (JOYFUL survey).
    Koga K; Fukui M; Fujisawa M; Suzukamo Y
    J Obstet Gynaecol Res; 2023 Oct; 49(10):2528-2537. PubMed ID: 37524334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multi-centre retrospective cohort study comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids. The HOPEFUL study.
    Hirst A; Dutton S; Wu O; Briggs A; Edwards C; Waldenmaier L; Maresh M; Nicholson A; McPherson K
    Health Technol Assess; 2008 Mar; 12(5):1-248, iii. PubMed ID: 18331704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of the selective progesterone receptor modulator asoprisnil for heavy menstrual bleeding with uterine fibroids: pooled analysis of two 12-month, placebo-controlled, randomized trials.
    Stewart EA; Diamond MP; Williams ARW; Carr BR; Myers ER; Feldman RA; Elger W; Mattia-Goldberg C; Schwefel BM; Chwalisz K
    Hum Reprod; 2019 Apr; 34(4):623-634. PubMed ID: 30865281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The responsiveness of the uterine fibroid symptom and health-related quality of life questionnaire (UFS-QOL).
    Harding G; Coyne KS; Thompson CL; Spies JB
    Health Qual Life Outcomes; 2008 Nov; 6():99. PubMed ID: 19014505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised trial of treating fibroids with either embolisation or myomectomy to measure the effect on quality of life among women wishing to avoid hysterectomy (the FEMME study): study protocol for a randomised controlled trial.
    McPherson K; Manyonda I; Lumsden MA; Belli AM; Moss J; Wu O; Middleton L; Daniels J
    Trials; 2014 Nov; 15():468. PubMed ID: 25432688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids.
    Sangkomkamhang US; Lumbiganon P; Laopaiboon M; Mol BW
    Cochrane Database Syst Rev; 2013 Feb; (2):CD008994. PubMed ID: 23450594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.